At Cyagen, we are a pioneer in the field of AAV gene therapy and ophthalmic research. Our cutting-edge technology utilizes the power of large language AI models to revolutionize discovery of novel Adeno-Associated Virus (AAV) vector designs, reshaping the way we target and treat ocular disorders.
Compared to traditional directed evolution, our AI-powered directed evolution utilizes the most advanced large-language models enabling a much shorter AAV discovery cycle with higher efficiency and multi-dimensional prediction capabilities.
Our AI model demonstrates exceptional prediction accuracy in AAV productivities and is able to produce novel AAV designs at high-titer yields, as validated by wet-lab experiments (Fig. 2), significantly lowering AAV manufacturing costs.
With exceptional prediction accuracy, our AI model successfully designed novel AAV vectors that outperform the clinically validated AAV2-7m8 in retinal penetration and whole eye transduction efficiency, providing better targeting AAVs for basic research and a platform for identifying more translatable gene therapy products for clinical use.
AAV-based gene therapy using our AI-designed novel AAV vector has shown remarkable efficacy in treating wet Age-Related Macular Degeneration (AMD) compared to both the WT AAV2 and to the FDA-approved Ranibizumab (Lucentis) in our humanized VEGF (hVEGF) mouse model.
Cyagen invites companies and research institutions focusing on AAV gene therapies for ophthalmic research to join us in shaping the future medicine for patients with genetic ocular diseases. Our mission is to empower your research and therapeutic development with the unmatched potential of AI-powered AAV vector discovery platform, redefining the possibilities for ophthalmology.
Ready to collaborate with the leaders in AI-powered AAV discovery for gene therapy? Contact us now to learn more about how our breakthrough CRO platform can accelerate your research journey towards revolutionary ocular treatments.